PROTAVIO MONOPROSOPI E.P.E

Their core work

Protavio is a Greek biotech SME specializing in proteomics and cellular pathway analysis, with a strong focus on cancer biology and age-related disease mechanisms. They contribute computational and experimental expertise to EU-funded training networks (MSCA), supporting early-stage researchers working on translational medicine challenges — from melanoma complexity to intervertebral disc degeneration. Their work sits at the intersection of bioinformatics, systems biology, and targeted therapy development, making them a niche partner for projects that need to bridge molecular research with clinical application.

What they specialise in

How they've shifted over time

In their early H2020 phase (2014-2018), Protavio focused on melanoma disease complexity and systems biology engineering — broadly foundational work in cancer and computational biology. From 2019 onward, their portfolio diversified significantly: they moved into aging-related diseases (progeria, neurodegeneration), membrane trafficking in tumor microenvironments, and musculoskeletal translational medicine. This shift suggests a company broadening from pure cancer research toward a wider translational medicine scope, particularly in cellular degradation pathways (mitophagy, autophagy) and computational biomechanics.

Protavio is moving toward computational translational medicine with increasing emphasis on cellular degradation mechanisms (autophagy, mitophagy) and their role in both cancer and age-related diseases.

How they like to work

Protavio operates exclusively as a participant — never as coordinator — in large MSCA training networks, which typically involve 10-15 partners. With 68 unique consortium partners across 19 countries from just 5 projects, they integrate into broad, pan-European consortia rather than leading small targeted collaborations. This profile suggests a reliable specialist contributor that brings specific technical capabilities to large multi-partner efforts without seeking administrative leadership.

Protavio has built a remarkably wide network for a small company: 68 unique partners across 19 countries from only 5 projects. This breadth comes from participation in large MSCA training networks, giving them connections across most of the EU research landscape in life sciences.

What sets them apart

Protavio is a rare example of a Greek biotech SME with consistent MSCA participation spanning a full decade of H2020. Their combination of proteomics expertise (the company name hints at protein analysis — "protATonce") with computational biology makes them a versatile partner for training networks that need industry-side hosting for early-stage researchers. For consortium builders, they offer a Greek SME slot with genuine life sciences capability, not just administrative participation.

Highlights from their portfolio

• SECRET
  Directly targets cancer therapy through secretory pathway exploitation — the most commercially translatable project in their portfolio, linking membrane trafficking research to tumor treatment.
• Disc4All
  Their most recent project (2020-2025) and a clear departure into mechanobiology and musculoskeletal medicine, signaling strategic diversification beyond oncology.
• HealthAge
  Bridges cancer expertise with aging research through shared cellular mechanisms (mitophagy, autophagy), showing how their core competencies connect across disease areas.